GSK sells stake in diagnostics firm to raise $1.7 billion
This article was originally published in Scrip
GlaxoSmithKline has sold its entire remaining stake in Quest Diagnostics, just under 31 million shares. GSK said that it had been considering the move for some time and had decided that now was "a good time to take advantage of favourable market conditions, thereby releasing funds from one of our non-core assets".
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.